Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
- that is the real message of today’s RNS.
For the first time in Sareum’s history, the company description is as follows:
“Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company ”
A significant milestone reached today.
Good luck all.
The links are correct. You just have to copy them and paste the URL into your browser.
It appears that LSE made some software changes over the weekend to make the boards work in a worse way.
Usually software changes are for the better and introduce new features, but that’s not the LSE way!
So, three MMs conspired for 20mins to hide three mid-sized trades, then one MM stepped in to correct it?
Ok. You’re welcome to believe what you like, but it would take more evidence than that to convince me :)
Wasn’t this asked at the last presentation?
If you go thru the recording, you can get it directly from Tim.
From memory, his response was along the lines of “they stopped returning our calls several months ago”.
I think that tells us all we need to know.
£Bn market cap is £14.70 @ 68M shares. This assumes no dilution / raising by equity issue. We can get there if 737 deal finances 1801 &1802.
GSK acquired Sierra for $1.9 Bn - that’s basically for one Ph3 product which was tested for just *one* indication.
Sareum potentially have two fully owned products for multiple indications plus a percentage of royalties for a third.
If, and I stress if, all goes perfectly, we could be looking at a multiplier of 3x the Sierra valuation. Multiply again for greater gross sale value as Sierra’s momelotenib was in a niche market?
Obviously lots of caveats apply, fair seas and a following wind :) but I don’t think anyone would turn their nose up at an SP of £45
GLA.